PZ99 thanks for your good points highlighted.I've seen some...

PZ99 thanks for your good points highlighted.

I've seen some broker reports that still refer to our original Prospectus in terms of original areas where we had patents in place. This has now been updated (see pic below) but I'm not sure about the Bene supply rights. I can assume that if we are the only ones that have patents for the treatment of BMEL in OA for example in certain areas such as Europe and US, Bene wouldn't supply to any competitors for treatment of the same patented conditions and any generics would have to undergo bio-equivalance which would involve separate trials. Please correct me if I'm wrong though. The report by Richard Moreland does go into a fair bit of detail but doesnt mention about the Bene rights and what areas it may relate to specifically.

We certainly need to know if the Bene supply contract has been expanded for other areas of the world, a good question perhaps at the next AGM or before.